Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Operating Income of -$5.08 million for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$5.08M | -7.0% |
| 2023 | -$4.75M | -83.3% |
| 2022 | -$2.59M | -35.2% |
| 2021 | -$1.92M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.27M | +12.7% | +6.1% |
| June 30, 2025 | -$1.36M | -42.5% | -2.2% |
| March 31, 2025 | -$1.33M | -9.0% | +9.0% |
| September 30, 2024 | -$1.46M | -7.6% | -53.3% |
| June 30, 2024 | -$952.2K | +39.6% | +21.8% |
| March 31, 2024 | -$1.22M | -12.3% | +10.3% |
| September 30, 2023 | -$1.36M | -90.4% | +13.9% |
| June 30, 2023 | -$1.58M | -101.7% | -45.3% |
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -7.0% in Operating Income compared to the prior fiscal year.
- Over the 2021–2024 period, LIPELLA PHARMACEUTICALS INC.’s operating income has declined by 165.2% (from -$1.92 million to -$5.08 million).
- The most recent figure is from LIPELLA PHARMACEUTICALS INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: